Mohammed Khan, MD
Ophthalmology · Plymouth Meeting, PANPI 1477844108
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,470 of the $6,000 with a category attached, or 74.5%. 10 manufacturers reported payments, led by Genentech, Inc. at 52.3% of the total. Reporting peaked in 2020 at $3,156 and has fallen 90.4% since, to $304 in 2025.
Across 14 payments — averaging $428.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$3K
- AbbVie$1K
- Boston Scientific$990
- Dutch Ophthalmic, USA$211
- Regeneron Healthcare Solutions, Inc.$122
- Johnson & Johnson Surgical Vision, Inc.$83
- plus $123 from 4 others
Across 12 payments — averaging $15,353 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$169K
- F. Hoffmann-la Roche AG$16K
What the payments were for
- Consulting fees$4,47075%
- Travel & lodging$77713%
- Food & beverage$75313%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 1 | $3,140 |
| AbbVie | 1 | $1,330 |
| Boston Scientific | 4 | $990 |
| Dutch Ophthalmic, USA | 2 | $211 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $83 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Genentech USA, Inc. | 1 | $20 |
| Organogenesis Inc. | 1 | $18 |
| GSK | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lucentis$3,140
- OZURDEX$1,330
- GENERAL - THERAPIES$777
- EVA, combined machine$166
- TISSUEBLUE$166
- WaveWriter Alpha Prime 16$123
- EYLEA$122
How this compares
$6,000 in reported general payments places this provider in the 80th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 121 | $6,422 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 19 | $378 |
| Ketorolac Tromethamine | 13 | $365 |
| Diclofenac Sodium | 15 | $204 |
| Brimonidine Tartrate | 11 | $144 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Plymouth Meeting
- Carl RegilloPlymouth Meeting$721K
- Michael KlufasPlymouth Meeting$393K
- Ajay KuriyanPlymouth Meeting$226K
- Allen HoPlymouth Meeting$225K
- Sunir GargPlymouth Meeting$216K
- Yoshihiro YonekawaPlymouth Meeting$95K
- Omesh GuptaPlymouth Meeting$85K
- Sonia MehtaPlymouth Meeting$49K
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.